Anticorps Polyclonal de lapin anti-COL4A2
COL4A2 Polyclonal Antibody for WB, IHC, IF-P, ELISA
Hôte / Isotype
Lapin / IgG
Réactivité testée
Humain et plus (1)
Applications
WB, IHC, IF-P, ELISA
Conjugaison
Non conjugué
N° de cat : 55131-1-AP
Synonymes
Galerie de données de validation
Applications testées
| Résultats positifs en WB | cellules HeLa | 
| Résultats positifs en IHC | tissu rénal humain,  tissu de cancer du sein humain,  tissu d'hyperplasie mammaire humain il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0. | 
| Résultats positifs en IF-P | tissu rénal humain, | 
Dilution recommandée
| Application | Dilution | 
|---|---|
| Western Blot (WB) | WB : 1:1000-1:6000 | 
| Immunohistochimie (IHC) | IHC : 1:1000-1:4000 | 
| Immunofluorescence (IF)-P | IF-P : 1:50-1:500 | 
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, check data in validation data gallery | |
Applications publiées
| IHC | See 22 publications below | 
| IF | See 14 publications below | 
Informations sur le produit
55131-1-AP cible COL4A2 dans les applications de WB, IHC, IF-P, ELISA et montre une réactivité avec des échantillons Humain
| Réactivité | Humain | 
| Réactivité citée | Humain, porc | 
| Hôte / Isotype | Lapin / IgG | 
| Clonalité | Polyclonal | 
| Type | Anticorps | 
| Immunogène | Peptide | 
| Nom complet | collagen, type IV, alpha 2 | 
| Masse moléculaire calculée | 168 kDa | 
| Poids moléculaire observé | 200 kDa | 
| Numéro d’acquisition GenBank | NM_001846 | 
| Symbole du gène | COL4A2 | 
| Identification du gène (NCBI) | 1284 | 
| Conjugaison | Non conjugué | 
| Forme | Liquide | 
| Méthode de purification | Purification par affinité contre l'antigène | 
| Tampon de stockage | PBS with 0.02% sodium azide and 50% glycerol | 
| Conditions de stockage | Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA. | 
Protocole
| Product Specific Protocols | |
|---|---|
| WB protocol for COL4A2 antibody 55131-1-AP | Download protocol | 
| IHC protocol for COL4A2 antibody 55131-1-AP | Download protocol | 
| IF protocol for COL4A2 antibody 55131-1-AP | Download protocol | 
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols | 
Publications
| Species | Application | Title | 
|---|---|---|
| EBioMedicine Aspirin targets P4HA2 through inhibiting NF-κB and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma. | ||
| ACS Appl Mater Interfaces Novel Thermosensitive Hydrogel Promotes Spinal Cord Repair by Regulating Mitochondrial Function. | ||
| Biomaterials Tumor-specific nitric oxide generator to amplify peroxynitrite based on highly penetrable nanoparticles for metastasis inhibition and enhanced cancer therapy. | ||
| Biofabrication Engineering microvasculature by 3D bioprinting of prevascularized spheroids in photo-crosslinkable gelatin. | ||
| Cell Mol Life Sci Macrophage Dectin-1 mediates Ang II renal injury through neutrophil migration and TGF-β1 secretion | 
Avis
The reviews below have been submitted by verified Proteintech customers who received an incentive for providing their feedback.
| FH Samantha (Verified Customer) (05-10-2024) | Clean bands detected in DRG and Spinal cord tissue of mice. 
 | 
| FH Pankhuri (Verified Customer) (08-22-2022) | Nice clean antibody. Did IF for collagen in NSCs organoid. The collagen fibres in the ECM of organoid were stained beautifully. 
  | 
| FH Lindsey (Verified Customer) (05-24-2021) | BULLETPROOF ANTIBODY! 
  | 
| FH Malak (Verified Customer) (02-24-2021) | This antibody works very well 
 | 
| FH Joshua (Verified Customer) (04-28-2019) | Vascular endothelial cells in 3D culture were fixed in paraformaldehdye and stained for collagen IV (red). DRAQ7 used as a counterstain (blue). As expected, collagen IV localized to the vascular basement membranes. 
  | 










